Pharmacological management of acute lymphoblastic leukemia in childhood
dc.contributor.advisor | Pórszász, Róbert | |
dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.contributor.author | Chen, Wei Jie | |
dc.contributor.department | DE--Gyógyszerésztudományi Kar | hu_HU |
dc.contributor.opponent | Drimba, László | |
dc.contributor.opponent | Megyeri, Attila | |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Aneszteziológiai és Intenzív Terápiás Tanszék | hu_HU |
dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
dc.date.accessioned | 2022-08-20T10:05:39Z | |
dc.date.available | 2022-08-20T10:05:39Z | |
dc.date.created | 2021-10-22 | |
dc.description.abstract | Acute Lymphoblastic Leukemia (ALL) is the most common hematological malignancy diagnosed in childhood. So as more and more new pediatric ALL treatments and regimens have been modified for better treatment options and outcomes. By reviewing the history, current status, and future prospects for the therapy of pediatric ALL, concentrating on interventions and biology while excluding children ALL and relapsed/refractory ALL, which have been reported in other cases, will help us have a better understanding of this major childhood cancer management. | hu_HU |
dc.description.corrector | hbk | |
dc.description.course | általános orvos | hu_HU |
dc.description.courselang | angol | hu_HU |
dc.description.degree | egységes, osztatlan | hu_HU |
dc.format.extent | 32 | hu_HU |
dc.identifier.uri | http://hdl.handle.net/2437/336649 | |
dc.language.iso | en | hu_HU |
dc.subject | ALL treatment | hu_HU |
dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
dc.title | Pharmacological management of acute lymphoblastic leukemia in childhood | hu_HU |